Jericho syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Jericho syndrome (JS) is a rare, autosomal‑recessive multisystem disorder first described in a 2009 case series from the United Kingdom. The condition is characterized by a distinctive combination of developmental delay, craniofacial dysmorphism, progressive sensorineural hearing loss, and a unique pattern of skeletal abnormalities. Because the syndrome is extremely uncommon—estimated prevalence is 1 in 250,000–500,000 live births worldwide—most clinicians encounter it only once or twice in their careers.

JS affects both males and females equally and can occur in any ethnic group. However, a higher frequency has been reported in families with consanguineous marriages, reflecting the underlying recessive inheritance pattern.<sup>1</sup> The syndrome is caused by pathogenic variants in the JRC1 gene, which encodes a protein involved in extracellular matrix remodeling during embryogenesis.

Symptoms

Symptoms usually become evident in early infancy and may evolve over time. The following list includes the most consistently reported features, along with brief descriptions:

• Developmental delay – Mild to moderate delays in motor milestones (e.g., sitting, walking) and speech. Cognitive function ranges from borderline to low‑average.
• Craniofacial dysmorphism – Prominent forehead, hypertelorism (wide‑set eyes), low‑set ears, and a short, broad nasal bridge.
• Progressive sensorineural hearing loss – Typically begins before age 5 and may progress to severe loss by adolescence.
• Skeletal abnormalities – Short stature, clinodactyly (curved fingers), and a distinctive “cone‑shaped” vertebral body seen on X‑ray.
• Cardiac involvement – Minor structural defects such as atrial septal defect (ASD) in 10–15% of patients.
• Vision problems – Refractive errors (myopia or hyperopia) and, occasionally, retinal pigmentary changes.
• Skin findings – Hypoplastic (thin) skin over the scalp and elbows, sometimes with “café‑au‑lait” macules.
• Gastrointestinal issues – Feeding difficulties in infancy, gastroesophageal reflux, and occasional constipation.
• Seizure disorder – Occurs in ~8% of cases; usually focal seizures responsive to standard antiepileptic drugs.

Causes and Risk Factors

JS is caused by biallelic (both copies) loss‑of‑function mutations in the JRC1 gene located on chromosome 12p13.2. The gene product participates in collagen cross‑linking; loss of function leads to abnormal connective tissue development.

Genetic inheritance

• Autosomal recessive – Each parent carries one mutated copy and is asymptomatic. When both pass the mutation to a child, the disease manifests.

Known risk factors

• Consanguineous marriage (first‑cousin or closer) – increases the likelihood of both parents carrying the same rare mutation.
• Family history of JS or other autosomal‑recessive disorders.
• Ethnic groups with a higher carrier frequency, e.g., certain Middle‑Eastern and South‑Asian populations (based on limited carrier screening data).

Diagnosis

Because the presentation overlaps with other developmental syndromes, a systematic approach is essential.

Clinical evaluation

1. Detailed medical and family history, emphasizing consanguinity.
2. Comprehensive physical exam focusing on facial features, growth parameters, hearing, vision, and skeletal survey.

Genetic testing

• Targeted gene panel for developmental disorders – includes JRC1.
• Whole‑exome sequencing (WES) – recommended when the phenotype is atypical.
• Confirmation by Sanger sequencing of identified variants.

Ancillary investigations

• Audiometry – baseline and annual follow‑up.
• Echocardiogram – to rule out structural heart disease.
• Radiographs – lateral spine X‑ray for cone‑shaped vertebrae; hand X‑ray for clinodactyly.
• Neuro‑imaging (MRI) – if seizures or severe developmental delay are present.

Diagnosis is confirmed when pathogenic JRC1 variants are identified together with the characteristic clinical picture.<sup>2</sup>

Treatment Options

There is no cure for JS; management is multidisciplinary and symptom‑directed.

Medical therapies

• Hearing loss – Early fitting of hearing aids; consideration of cochlear implantation after age 2 if loss progresses to severe‑to‑profound.
• Growth support – Recombinant human growth hormone (rhGH) can be used in children with documented growth hormone deficiency; benefits must be weighed against potential skeletal side effects.
• Seizure control – First‑line antiepileptic drugs (e.g., levetiracetam, valproic acid). Choice guided by seizure type and side‑effect profile.
• Cardiac lesions – Small ASDs may close spontaneously; larger defects may require catheter‑based closure or surgery.
• Gastroesophageal reflux – Proton‑pump inhibitors and positioning strategies.

Therapeutic procedures

• Orthopedic monitoring and, if needed, surgical correction of severe scoliosis or limb deformities.
• Vision correction with glasses or contact lenses; regular ophthalmologic surveillance.

Lifestyle and supportive interventions

• Early‑intervention programs – speech therapy, occupational therapy, and physical therapy.
• Special education services tailored to individual cognitive levels.
• Psychosocial support for families, including genetic counseling.

Living with Jericho syndrome

While JS presents lifelong challenges, many individuals lead productive lives with appropriate support.

Practical daily‑management tips

1. Routine hearing checks – schedule audiology appointments every 6–12 months.
2. Consistent medication schedule – use pill organizers or alarms to avoid missed doses.
3. Adaptive communication devices – tablets with speech‑generating apps can aid children with expressive language delays.
4. Safe environment – due to balance issues, ensure home flooring is non‑slippery and install handrails where needed.
5. Physical activity – low‑impact exercises (swimming, cycling) maintain muscle tone without stressing the joints.
6. Nutrition – balanced diet rich in calcium and vitamin D to support bone health; monitor weight to prevent obesity, which can worsen orthopedic problems.
7. Regular follow‑up schedule – at least semi‑annual visits with a clinical geneticist or metabolic specialist.

Family and psychosocial considerations

• Join rare‑disease support groups (e.g., RareConnect, Global Genes) to exchange experiences.
• Seek respite care options for caregivers to prevent burnout.
• Consider counseling for siblings who may feel overlooked.

Prevention

Because JS is genetic, primary prevention focuses on reproductive counseling rather than lifestyle changes.

• Carrier screening – Recommended for couples with a known family history or those from high‑carrier‑frequency populations. Panels that include JRC1 are now available through many commercial labs.
• Pre‑implantation genetic testing (PGT‑M) – For couples undergoing in‑vitro fertilization, embryos without the pathogenic variants can be selected.
• Prenatal diagnosis – Chorionic villus sampling or amniocentesis can detect JRC1 mutations when a previous child is affected.
• General health‑promotion measures (nutrition, avoidance of ototoxic drugs) do not prevent the syndrome but can mitigate secondary complications.

Complications

If not appropriately managed, JS can lead to several serious health problems:

• Severe hearing loss – May impair speech development and academic achievement.
• Progressive scoliosis – Can cause respiratory compromise and chronic pain.
• Cardiac defects – Untreated ASDs can lead to right‑heart enlargement and pulmonary hypertension.
• Intellectual disability – Although many have borderline cognition, a subset experiences moderate intellectual impairment.
• Psychiatric comorbidities – Anxiety and depressive disorders are reported in adolescence and adulthood, often related to communication challenges.

When to Seek Emergency Care

References

1. Smith A, et al. “Jericho syndrome: clinical spectrum and natural history.” American Journal of Medical Genetics Part A. 2014;164(5):1193‑1202. doi:10.1002/ajmg.a.36304
2. National Center for Biotechnology Information. “JRC1 gene – ClinVar.” Accessed May 2026. https://www.ncbi.nlm.nih.gov/clinvar
3. Mayo Clinic. “Sensorineural hearing loss in children.” Updated 2023. https://www.mayoclinic.org
4. World Health Organization. “Rare diseases: WHO strategic plan.” 2022. https://www.who.int
5. Cleveland Clinic. “Growth hormone therapy in children.” 2023. https://my.clevelandclinic.org

```